These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 3589691

  • 1. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
    Liliemark JO, Gahrton G, Paul CY, Peterson CO.
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
    [Abstract] [Full Text] [Related]

  • 2. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 3. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Plunkett W, Dixon DO.
    Cancer Res; 1985 Nov 01; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [Abstract] [Full Text] [Related]

  • 4. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 01; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 5. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
    Plunkett W, Liliemark JO, Estey E, Keating MJ.
    Semin Oncol; 1987 Jun 01; 14(2 Suppl 1):159-66. PubMed ID: 3589690
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 May 01; 92(5):546-53. PubMed ID: 11376564
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Paul CY, Gahrton CG, Peterson CO.
    Cancer Res; 1985 May 01; 45(5):2373-5. PubMed ID: 3986778
    [Abstract] [Full Text] [Related]

  • 8. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 01; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 9. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.
    Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrzosek C, Early AP, Preisler H.
    Med Pediatr Oncol; 1982 Mar 01; 10 Suppl 1():33-43. PubMed ID: 7162465
    [Abstract] [Full Text] [Related]

  • 10. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 11. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
    Plunkett W, Keating M.
    Adv Exp Med Biol; 1986 Dec 15; 195 Pt B():171-5. PubMed ID: 3766228
    [No Abstract] [Full Text] [Related]

  • 12. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 13. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
    Riva-Lavieille C, Ressayre C, Barra Y, Carcassonne Y, Iliadis A.
    Ther Drug Monit; 1994 Aug 15; 16(4):375-9. PubMed ID: 7974627
    [Abstract] [Full Text] [Related]

  • 14. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 Sep 15; 92(9):975-82. PubMed ID: 11572766
    [Abstract] [Full Text] [Related]

  • 15. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M.
    Leukemia; 1987 Sep 15; 1(9):638-43. PubMed ID: 3478543
    [Abstract] [Full Text] [Related]

  • 16. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 15; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 17. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 15; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 18. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T, Kobayashi K, Okabe Y, Okumura H, Matano S, Kanno M, Takeda Y, Ohtake S, Nakamura S, Matuda T.
    J Clin Pharmacol; 1994 Jan 15; 34(1):52-9. PubMed ID: 8132852
    [Abstract] [Full Text] [Related]

  • 19. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T, Kobayashi K, Nakamura S, Ohtake S, Itoh K, Kanno M, Hirai J, Yasushi, Matsuda TT.
    Gan To Kagaku Ryoho; 1988 Apr 15; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [Abstract] [Full Text] [Related]

  • 20. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V, Robertson LE, Keating MJ, Plunkett W.
    Cancer Chemother Pharmacol; 1994 Apr 15; 34(1):30-6. PubMed ID: 8174200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.